NEOGEN CHEMICALS
BSE ticker code |
542665 |
NSE ticker code |
NEOGEN |
Major activity |
Speciality Chemicals |
Managing Director |
Haridas Thakarshi Kanani |
Equity capital |
Rs. 23.34 crore; FV Rs. 10 |
52 week high/low |
Rs. 1380 / Rs. 600 |
CMP |
Rs. 1259.90 |
Market Capitalisation |
Rs. 2939.93 crore |
Recommendation |
Buy at declines |
Pole player in speciality chem
Neogen Chemicals is a leading manufacturer of speciality chemicals based on bromine and
lithium. Starting in 1991 at
Mhape in Navi Mumbai with the manufacture of a few bromine
and lithium compounds, the company has during the last three
decades expanded its range of products to around 200 today,
comprising 182 organic and 19 inorganic chemicals. In addition,
the company also undertakes custom
synthesis and contract manufacturing of
speciality chemicals. Its prospects going
ahead are exciting.
Consider:
-
z Neogen is a leading speciality chemicals company and this industry segment
is offering multifold
returns to investors. Share prices of
almost all speciality companies are
at sky-high levels and prospects for
this segment are highly promising.
Till a couple of years ago, China was
the uncrowned king in supplying speciality chemicals to global consumers. But
on account of a stiff environmental-friendly policy of the Beijing government,
there has been a sharp fall in production by Chinese companies. At the
same time, global chemical players have
felt the need to diversify the sources of
imports and have started adopting a
‘China plus one’ policy to meet their requirements. India, thanks to its
excellent
quality of products and manufacturing competitiveness, has
emerged as a leading alternative supplier of speciality chemicals to global
consumers. According to experts, the unprecedented boom in speciality chemicals
will continue unabated
till at least 2027. In short, the outlook for Neogen is bullish
at present.
-
z The company operates from two modern manufacturing facilities — at Mhape in
Navi Mumbai of Maharashtra
and at Karhadi in Vadodara of Gujarat. Neogen has set up a
third greenfield manufacturing facility at Dahej in Gujarat, which
has recently gone on stream. At the same time, the company has
also embarked upon an expansion plan for the Vadodara plant.
These additional capacities will give a big boost to the company’s
topline as well as bottomline at a time when the demand for its
products is steadily on the rise.
-
z Three decades ago, the
company had started with 4 to 5 products, which went up to 20 products by
2001, and the current product portfolio is around 200. At the same time, the
company’s customer base is also on the
rise and has by now reached to 1,363,
of which about 1,237 are domestic customers and 126 international customers.
These customers are spread across
a wide array of application industries,
including pharmaceuticals, agrochemicals, aroma chemicals, electrical
chemicals, speciality polymers, construction
chemicals and VAM original equipment
manufacturers. Among the major customers are Austin Chemical of the US, CBC
of Japan, and DIVI’s Laboratories,
Laurus Labs, Solway Specialities India,
Thermal and Voltas – all of India. The
number of customers is on the rise.
-
z Besides expanding its manufacturing and marketing its speciality chemicals
products, the company
has planned to increase the size and scale of its contract research
and manufacturing business over the next few years and is in
discussions with various companies in Europe and Japan to develop their
proprietary products, for which the company has already executed non-disclosure
and secrecy agreements.
-
z Neogen’s finances are growing steadily. During the
last five years, its sales turnover has expanded from Rs 121
crore in fiscal 2021 with the profit at net level shooting up from
Rs 7.75 crore to Rs 31.44 crore during this
period. The company’s financial position
is getting stronger by the day. As on March
31, 2021, its reserves stood at Rs 133.40
crore, almost six times its equity capital of
Rs. 23.33 crore. Prospects ahead are very
bright and we expect an EPS of Rs 20
within a couple of years.
PERFORMANCE INDICATORS (Rs. in crore)
Year
|
Net Sales
|
Net Profit
|
EPS (Rs.)
|
Div (%)
|
BV (%)
|
RONW (%)
|
2018-19
|
239.10
|
21.00
|
9.00
|
15.0
|
60.70
|
34.80
|
2019-20
|
306.10
|
28.70
|
12.30
|
20.0
|
67.00
|
25.30
|
2020-21(E)
|
336.42
|
31.33
|
13.40
|
23.0
|
78.40
|
18.47
|
2021-22(E)
|
412.40
|
35.46
|
15.21
|
25.0
|
81.10
|
20.15
|
INDO AMINES LTD
BSE ticker code |
524648 |
NSE ticker code |
-- |
Major activity |
Commodity Chemicals |
Chairman |
Vijay Palkar |
Equity capital |
Rs. 35.35 crore; FV Rs. 10 |
52 week high/low |
Rs. 375 / Rs. 49 |
CMP |
Rs. 254.00 |
Market Capitalisation |
Rs. 897.86 crore |
Recommendation |
Buy at declines |
Riding speciality chem demand
Indo Amines is one of India’s largest manufacturers of organic and inorganic chemical
compounds. To be specific, it
manufactures fine, speciality and performance chemicals,
providing a package of products and technical services for
the domestic and global markets. The company also manufactures perfumery chemicals and
active pharmaceutical ingredients. Prospects for the company
are highly promising.
Consider:
-
z The company is one of
India’s largest manufacturers of various amino acids, biogenic amines,
trimethylamine and aniline. The
company’s products are being used
in several industries, including agrochemicals, fertilisers, pesticides,
petrochemicals, dyes and intermediates,
and road construction companies.
Thus, the business prospects for the
company are quite encouraging.
-
z Indo Amines strives to be a
best-in-class chemical manufacturing
company by adopting an innovation approach with great technical competency.
The company has ten state-of-the-art
manufacturing facilities, with four new
sites under construction. The Department
of Scientific and Industrial Research has
already approved the company’s R&D
laboratory. Here, the company strives to
develop new products among fine chemicals, alcohols,
cycloalkanes, amine hydrochlorides, etc. A few years ago, the
company received approval for 10 speciality chemicals from a
US environment body. This approval has pushed up the demand
for these products immensely in the American market.
-
z Needless to say, the company’s financial performance
is growing steadily. During the last five years, its sales turnover
(standalone) has expanded from Rs 279 crore in fiscal 2017 to
Rs 539 crore – almost double – with the profit at net level shooting up from Rs
14 crore to Rs 33 crore during this period. The
company’s financial position is improving steadily, with reserves
at the end of March 2021 standing at Rs 124 crore as against
its equity capital of Rs 35.35 crore. This is virtually a debt-free
company with its interest burden for the year ended March
2021 being negligible at Rs 3.74
crore.
-
z India’s chemical industry is on the fast track due to the
steady disappearance of China from
the global export scene. Growing
environmental concerns in China
and a government crackdown there
on chemical manufacturers have
brought down China’s exports of
chemicals, opening the global market for countries like India. Again,
the demand for speciality chemicals
is on the rise in international markets and
Indian companies like Indo Amines have
started manufacturing speciality chemicals of topmost quality. Indo Amines has
been steadily raising its exports. At the
same time, global consumers, concerned
over China’s role in spreading the
coronavirus, have started adopting a
‘China plus one’ policy in order not to
depend on China alone for the supply of
chemicals. This development has given a big boost to speciality chemicals
companies in India like Indo Amines.
As expected, the company has started the new fiscal
year (2022) on a buoyant note with sales in Q1FY22 jumping by almost 72 per cent to Rs
183 crore and net profit
inching up by over 24 per cent to Rs 8.48 crore. Prospects for the period going ahead
are considered all the
better as the global demand for Indian speciality chemicals is steadily going up.
During the last one year,
the stock price has multiplied by over 5 times –
from around Rs 50 to Rs
270. There is still some
steam left. Buy at every
decline.
CONSOLIDATED PERFORMANCE INDICATORS (Rs. in crore)
Year
|
Net Sales
|
Net Profit
|
EPS (Rs.)
|
Div (%)
|
BV (%)
|
RONW (%)
|
2018-2019
|
470.90
|
22.70
|
6.80
|
10.0
|
29.90
|
26.60
|
2019-2020
|
478.75
|
12.81
|
3.60
|
10.0
|
37.80
|
27.45
|
2020-2021(E)
|
540.43
|
37.41
|
10.60
|
11.0
|
45.70
|
25.55
|
2021-2022(E)
|
576.15
|
39.10
|
12.11
|
12.0
|
48.10
|
26.40
|
ORIENT PAPER
BSE ticker code |
502420 |
NSE ticker code |
ORIENTPPR |
Major activity |
Paper & Paper Products |
Managing Director |
Manohar Lal Pachisia |
Equity capital |
Rs. 21.22 crore; FV Re. 01 |
52 week high/low |
Rs. 34 / Rs. 15 |
CMP |
Rs. 29.20 |
Market Capitalisation |
Rs. 619.58 crore |
Recommendation |
Buy at declines |
Rs 225 crore capex will boost RoCE
Orient Paper and Industries, a CK Birla group company, is a
leading manufacturer of paper with a capacity of 105 ktpa,
of which printing and writing paper accounts for 55 ktpa
and tissue paper 50 ktpa. The company is doing well and its
prospects going ahead are all the more promising.
Consider:
-
z With its 50 ktpa capacity, Orient is the largest producer of tissue paper in
the country.
Today, tissue paper has emerged as
the fastest growing segment in the
country, growing at a rate of 12 per
cent per annum – almost double the
size of the paper industry which is
growing at a rate of 6 per cent. With
growing incomes, improving standards of living and increasing hygiene
awareness, and growing export demand for Indian products,
the prospects for the tissue paper segment are steadily improving.
-
z Global demand for Indian tissue paper is growing as
pulp prices have spurted globally
while in India they are on the decline. These opposite trends in the
prices of the raw material for paper have boosted global demand
for Indian tissue paper. And
though a late entrant, OPIL has
already cornered almost 47 per
cent of the export market and its
share continues to grow.
-
z There has been a marked drop in demand for paper during the pandemic period.
But the re-opening of
schools and colleges is expected to revive demand for writing and printing
paper. According to the management of the
company, demand for writing and printing paper had turned
slack on account of closure of educational institutions and
offices, forcing the company to run its machines for W&P
paper at 70-75 per cent capacity. With the impact of the
pandemic receding, and with schools and colleges reopening, demand for this
paper segment has started reviving,
more so when viewed in the context of the New Education
Policy.
-
z Going ahead, the
company’s profitability is expected to
rise on account of: (a) ramping up its
new tissue paper production to full
capacity; (b) improved realisations
due to firm global pulp prices and a
weak rupee vis-à-vis weak raw material costs due to the increased focus
on the farm forestry programme; (c) a
better product mix with tissue paper’s
revenue share slated to improve from
33-42 per cent in fiscal 2020 to
around 50 per cent in fiscal 2023,
and (d) benefits accruing from operating leverage. The company’s
RoCE (return on capital employed)
is projected to improve from 26 per
cent in fiscal 2020 to 30 per cent in
the fiscal 2023.
-
z The company has
planned to enhance its pulp capacity from 72.5 ktpa to 100 ktpa,
in order to eliminate its reliance
on market pulp, at a cost of Rs 75
crore and by setting up a new recovery boiler at a cost of Rs 150 crore.
Despite this capex, the
company’s balance sheet will remain light and comfortable
as the capex would be funded out of internal accruals and/or
divestment of the company’s stake in Century Textile and
Industries. And the company will generate an RoCE of around
20 per cent for the new tissue paper facility due to the new
capex on brownfield expansion. The company would now
enhance its tissue paper capacity by 25
ktpa at a minimal cost in future due to a
huge land bank at its existing site as well
as surplus power capacity.
The stock is available at an attractive
price. Investment in this scrip will enable
a shareholder to reap rich benefits in the
long term.
PERFORMANCE INDICATORS (Rs. in crore)
Year
|
Net Series
|
Net Profit
|
EPS (Rs.)
|
Div (%)
|
BV (%)
|
RONW (%)
|
2018-19
|
710.00
|
84.30
|
4.00
|
110.0
|
63.20
|
8.00
|
2019-20
|
606.56
|
20.01
|
0.90
|
50.0
|
51.40
|
1.84
|
2020-21(E)
|
443.36
|
-46.55
|
--
|
25.0
|
49.10
|
-
|
2021-22(E)
|
590.40
|
10.32
|
--
|
25.0
|
50.30
|
1.11
|